Ed hates cancer and he’ll tell you as much. He was diagnosed with non-small cell lung cancer, the same disease that took his mother. At the time he was diagnosed, Ed’s cancer had advanced to stage 3. From the moment he discovered he had cancer Ed knew he needed to go beyond traditional treatments to beat it. Ed’s oncologist asked him to consider trying IMFINZI (durvalumab). Ed’s cancer has now been eradicated and he believes immunotherapy is opening doors for patients to live longer.
How Breakthroughs in Immunotherapy are Helping Non-Small Cell Lung Cancer Patients Live Longer
Stay up to date
Join our email list for updates on cancer immunotherapy research, events, and opportunities to get involved with the Cancer Research Institute. Sign up below and be a force for change in the fight against cancer.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.
